Biotech & Health Tech
STAT+: Ultragenyx cuts staff after another study fails
Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.
Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.
This is a summary of the story. Read the full article at Stat News (Biotech & Health Tech) ↗